IMR Press / FBL / Volume 4 / Issue 1 / DOI: 10.2741/kalish

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
A new CD44V3-containing isoform is involved in tumor cell growth and migration during human breast carcinoma progression
Show Less
1 Department of Cell Biology and Anatomy, University of Miami, School of Medicine, Miami, Florida
2 Division of Surgical Oncology, Department of Surgery, University of Miami School of Medicine, Miami, Florida
3 Department of Surgery, Medical Center of Delaware, Wilmington, Delaware
Front. Biosci. (Landmark Ed) 1999, 4(1), 1–8; https://doi.org/10.2741/kalish
Published: 1 January 1999
Abstract

CD44 isoforms belong to a family of cell adhesion molecules expressed on the cell surface of many tumor cells during human breast cancer progression. In this study we have analyzed the expression of CD44v3-containing isoforms [containing heparan sulfate addition sites for growth factor binding] in primary breast tumors, axillary nodal metastases and normal breast tissue. Using reverse transcriptase-polymerase chain reaction (RT-PCR) followed by Southern blot, cloning, nucleotide sequencing and RT-in situ-PCR analyses, we have found that at least two CD44v3-containing isoforms, including one new species of CD44v2,∆v3-10 (deltav3 defined as a v3 exon lacking the first 24 base pairs) and another previously reported CD44v3,8-10 are preferentially expressed in human primary breast tumor and axillary nodal metastases but not in normal breast tissues. These finding suggest that these CD44v3-containing isoforms are closely associated with breast cancer metastasis. Furthermore, we have established a stable transfection of CD44v2,∆v3-10 cDNA into non-metastatic human breast tumor cells (MCF-7) which contain endogenous CD44E isoform. Our results indicate that expression of CD44v2,∆v3-10 in MCF-7 cells promotes tumor cells to undergo rapid cell growth and active cell migration. Treatments of MCF-7 transfectants expressing CD44v2,∆v3- 10 with various agents such as anti-CD44v3 antibody, cytochalasin D (a microfilament disrupting agent known to prevent actin polymerization) and W-7 (a calmodulin antagonist) but not colchicine (a microtubule inhibitor), cause a significant inhibition of tumor cell migration. These findings suggest that CD44v2,∆v3-10 (related to human metastatic breast cancers) and associated microfilament components play an important role in the regulation of breast tumor cell behaviors required for the progression of human breast carcinomas.

Keywords
CD44
RT-PCR
Southern Blot
Alternative Splicing
Breast Cancers
Metastases
Tumor Cell Migration
Share
Back to top